Clorox (NYSE:CLX) Price Target Raised to $136.00

Clorox (NYSE:CLX) had its price target upped by Morgan Stanley from $125.00 to $136.00 in a research note issued to investors on Thursday,Benzinga reports. Morgan Stanley currently has an equal weight rating on the stock.

A number of other research analysts have also recently commented on the company. TD Cowen reaffirmed a “hold” rating on shares of Clorox in a research note on Thursday, January 8th. Royal Bank Of Canada set a $132.00 price objective on Clorox in a report on Wednesday. Citigroup upped their price objective on Clorox from $109.00 to $115.00 and gave the company a “neutral” rating in a research report on Wednesday. Jefferies Financial Group reduced their target price on Clorox from $152.00 to $151.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Zacks Research raised shares of Clorox from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. One analyst has rated the stock with a Buy rating, ten have issued a Hold rating and five have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $117.93.

Clorox Trading Up 1.6%

Shares of CLX stock opened at $119.52 on Thursday. The company has a current ratio of 0.74, a quick ratio of 0.50 and a debt-to-equity ratio of 71.03. The stock has a market capitalization of $14.45 billion, a price-to-earnings ratio of 19.53, a price-to-earnings-growth ratio of 0.58 and a beta of 0.59. Clorox has a 12-month low of $96.66 and a 12-month high of $159.04. The stock’s 50-day moving average price is $105.83 and its 200-day moving average price is $113.86.

Clorox (NYSE:CLX) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.39 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.04). Clorox had a net margin of 11.17% and a return on equity of 383.01%. The firm had revenue of $1.67 billion for the quarter, compared to analysts’ expectations of $1.64 billion. During the same quarter in the prior year, the business earned $1.55 EPS. The business’s quarterly revenue was down .8% compared to the same quarter last year. Equities research analysts predict that Clorox will post 7.15 EPS for the current fiscal year.

Clorox Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Wednesday, January 28th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 4.1%. The ex-dividend date is Wednesday, January 28th. Clorox’s dividend payout ratio is presently 81.05%.

Insider Buying and Selling

In other Clorox news, Director Pierre R. Breber purchased 4,000 shares of Clorox stock in a transaction dated Friday, November 21st. The stock was acquired at an average price of $104.13 per share, for a total transaction of $416,520.00. Following the acquisition, the director owned 13,000 shares in the company, valued at $1,353,690. This trade represents a 44.44% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.63% of the company’s stock.

Hedge Funds Weigh In On Clorox

Several institutional investors have recently bought and sold shares of CLX. Savvy Advisors Inc. boosted its position in Clorox by 1.4% during the 2nd quarter. Savvy Advisors Inc. now owns 6,395 shares of the company’s stock valued at $768,000 after acquiring an additional 91 shares in the last quarter. Canandaigua National Bank & Trust Co. lifted its stake in shares of Clorox by 0.8% during the 3rd quarter. Canandaigua National Bank & Trust Co. now owns 11,196 shares of the company’s stock worth $1,380,000 after purchasing an additional 94 shares during the last quarter. State of Michigan Retirement System boosted its position in Clorox by 0.3% during the second quarter. State of Michigan Retirement System now owns 33,551 shares of the company’s stock valued at $4,028,000 after purchasing an additional 100 shares in the last quarter. Field & Main Bank boosted its position in Clorox by 3.3% during the fourth quarter. Field & Main Bank now owns 3,100 shares of the company’s stock valued at $313,000 after purchasing an additional 100 shares in the last quarter. Finally, Fisher Asset Management LLC grew its stake in Clorox by 1.7% in the third quarter. Fisher Asset Management LLC now owns 6,053 shares of the company’s stock valued at $746,000 after purchasing an additional 102 shares during the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Clorox News Summary

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Morgan Stanley raised its price target on CLX to $136 (maintained equal-weight), citing valuation/earnings dynamics — a catalyst supporting the stock’s rally. Clorox (NYSE:CLX) Price Target Raised to $136.00 at Morgan Stanley
• Positive Sentiment: Investor write-ups are bullish: a Seeking Alpha piece frames CLX as a defensive, dividend-rich value after “solid” Q2 results and attractive valuation — supporting buy interest from income-focused investors. Clorox: Solid Q2 Results And Cheap Valuation MakesThis Defensive Dividend Stock A Strong Buy
• Neutral Sentiment: TD Cowen nudged its price target to $111 and kept a Hold rating — a modest recalibration that tempers upside expectations despite the recent positive headlines. TD Cowen Adjusts Clorox Price Target
• Neutral Sentiment: Company reported mixed Q2 results and reaffirmed its 2026 outlook — revenue roughly flat year-over-year and an EPS miss by a few cents; reassurances on the outlook limit downside but leave questions on near-term margin recovery. Clorox Posts Mixed Q2 Results, Reaffirms 2026 Outlook
• Neutral Sentiment: Management is weighing a potential GOJO acquisition and finishing an ERP implementation; strategic moves could boost long-term growth but add execution risk in the near term. Clorox Weighs GOJO Deal And ERP Finish Against Softer Earnings
• Neutral Sentiment: Q2 earnings call transcript is available for deeper read on management commentary around pricing, cost savings and margin plans — useful for gauging execution risk. Clorox (CLX) Q2 2026 Earnings Call Transcript
• Negative Sentiment: Some brokerages have a consensus “Reduce” rating on CLX, which may cap upside as institutional flows react to conservative guidance and margin concerns. The Clorox Company Given Consensus Rating of “Reduce” by Brokerages
• Negative Sentiment: BofA flagged margin uncertainty after the Q2 EPS miss — a reminder that cost and margin recovery, not just revenue, will drive forecast revisions and investor sentiment. BofA Flags Margin Uncertainty for Clorox After Q2 Earnings Miss
• Neutral Sentiment: A Zacks piece highlights using its Earnings ESP tool to find staples stocks that might beat — general market research, not CLX-specific guidance, but could affect short-term trading interest. Why Investors Need to Take Advantage of These 2 Consumer Staples Stocks Now

Clorox Company Profile

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.